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Abstract This investigation was aimed to probe the
pharmacological base of medicinal use of Acorus calamus
in ischemic heart diseases. Effect on heart parameters was
studied in isolated rabbit heart while coronary vasodilator
effect was studied in isolated bovine coronary arterial
rings, suspended in tissue baths filled with Krebs solution,
maintained at 37C, aerated with carbogen and responses
were measured on PowerLab data acquisition system. In
Langendorrf’s perfused rabbit heart, the crude extract of
Acorus calamus (Ac.Cr) at 0.01–10 mg/mL partially sup-
pressed force of ventricular contractions (FVC), heart rate
(HR) and coronary flow (CF). The ethylacetate fraction
completely suppressed FVC, partially suppressed HR and
CF, while the nHexane fraction exhibited similar effect on
FVC and HR but increased CF, similar to methacholine and
arachidonic acid. In bovine coronary arterial preparations,
Ac.Cr caused inhibition of U46619 (20 nM)-precontrac-
tions, which was blocked in presence of increasing con-
centration of K? (4.8–20 mM), tetraethylammonium
(1 lM) and SKF525A (10 lM), similar to arachidonic acid
and methacholine, indicating K? channels activation and
possible involvement of endothelial-derived hyperpolariz-
ing factor (EDHF). Activity-directed fractionation revealed
that EDHF-mediated activity is concentrated in the nHex-
ane fraction. When tested against high K?, the ethylacetate
fraction was found more potent than parent crude extract
and nHexane fraction. These data indicate that Ac.Cr
mediates coronary vasodilator effect primarily through
EDHF, responsible for the increase in CF, while the cardiac
depressant effects may be due to the presence of additional
cardiac depressant constituent(s), thus provides possible
mechanistic basis to its medicinal use in ischemic heart
diseases.
Keywords Acorus calamus  EDHF  K? channels 
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Introduction
Acorus calamus L. (Araceae), commonly known as ‘‘Sweet
flag’’, has been known since 2000 years, Ibn Sina called it
waj and Dioskurides akopov. A description of the plant
exists in the Theatrum Botanicum of J. Parkinson (1640)
and it has been listed since then in a number of Pharma-
copoeia and Codices, like British Pharmaceutical Codex,
1934 [1]. The plant was established in England as a wild
plant, commonly found in moist habitats throughout North
America, Europe and Central Asia. It has been taken over
the centuries as a remedy to treat various ailments [2]. The
roots and rhizomes of this plant have been used in the
Ayurvedic medicine, as well in this part of the world for
cardiovascular disorders, such as, ischemic heart diseases
[3].
Phytochemistry of the plant revealed the presence of
glucoside, alkaloid and essential oil containing calamen,
calamenol, calameon, asarone and sesquiterpenes [4]. It is
also known to contain a better glycoside named acorine
along with eugenol, pinene and camphene [5].
The plant is reported in the past for many biological
activities, including, antimicrobial [6], antidiarrhoeal [7],
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dyslipidemic [8], neuroprotective [9], antioxidant [10],
anticholinesterase [11], wound healing [12] and we repor-
ted as spasmolytic [13] hypotensive and vascular modula-
tor [14]. As an extension of our previous work [14], this
investigation was undertaken to study the mecha-
nism(s) responsible for the medicinal use of Acorus cala-
mus in ischemic heart diseases by using isolated rabbit
heart and bovine coronary artery. We have determined the
functional nature of the coronary vascular relaxation being
of endothelial origin and mediated through the endothelial-
derived hyperpolarizing factor (EDHF).
Materials and methods
Plant materials
Rhizomes of Acorus calamus (3.12 kg) were collected in
Swat District, KhyberPukhtonkhwa (formally, N.W.F.P.),
Pakistan in November 2004 and authenticated by Assistant
Professor Mr. Mehboob-ur-Rehman at the Department of
Botany, Govt. PG Jehanzeb College Saidu Sharif Swat,
Pakistan. A voucher specimen (A 200) was deposited at the
herbarium of the same Department.
Preparation of crude extract and fractionation
The powdered material about 1.70 kg was soaked in 70%
aqueous-methanol for 3 days with occasional shaking. It
was then filtered through a muslin cloth and then through a
Whatman qualitative grade 1 filter paper. This procedure
was repeated thrice and the combined filtrate was evapo-
rated on rotary evaporator at 35–40C under reduced
pressure (-760 mmHg) to a thick, semi-solid mass of dark
brown color; i.e. the crude extract (Ac.Cr), yielding
approximately 10%.
Activity-directed fractionation of the crude extract
was carried out by standard phytochemical procedures,
using different organic solvents [15–17]. A known
quantity of the extract (49.44 g) was dissolved in
100 mL of distilled water. This was transferred to a
separating funnel. nHexane (50–70 mL) was then added.
The mixture was shaken vigorously with regular allow-
ing the air to escape out. It was kept for about 30 min to
let the two layers separate. The upper layer of nHexane
was acquired and the same procedure was repeated twice
more and all the nHexane layers were collected and
concentrated in a rotary evaporator to obtain the nHex-
ane fraction (23.6%). Similarly, ethylacetate fraction
(30%) was also obtained.
Ac.Cr and its fractions were solubilized in distilled
water and 10% dimethyl sulfoxide (DMSO), respectively,
for use in the in vitro experiments.
Drugs and standards
The following reference chemicals were obtained from the
sources specified: arachidonic acid, methacholine chloride,
9-11-dideoxy-9a, 11a methanoepoxyprostaglandin F2a
solution (U46619), tetraethylammonium (TEA) bromide,
and SKF525A hydrochloride (Wako Chemicals, Japan).
Heparin from Leo Pharmaceutical Products, Denmark.
Verapamil hydrochloride, glibenclamide, indomethacin,
Nx-nitro-L-arginine methyl ester (L-NAME) and DMSO
from Sigma Chemical Company, USA. All chemicals used
were of the highest purity grade. Stock solutions of all the
chemicals were made in distilled water/suitable solvent and
the dilutions were made fresh on the day of experiment.
Animals
Experiments performed complied with the rulings of the
Institute of Laboratory Animal Resources, Commission on
Life Sciences, National Research Council [18] and
approved by the Ethical Committee of Aga Khan Univer-
sity Karachi. Local male rabbits (1–1.5 kg) used in the
study were bred and housed at the Animal house of Aga
Khan University under controlled environment (23–25C).
Animals were given tap water ad libitum and a standard
diet.
The bovine hearts were collected from freshly slaughter
animal in normal Krebs solution and coronary vessel was
excised out and trimmed from the extravascular tissues in
the laboratory.
Isolated tissue preparations
Langendorrf’s perfused isolated rabbit heart
As described previously [19, 20] male healthy rabbits
(1–1.5 kg) were injected (i.p) heparin (5000 IU) 1 h prior
of cervical dislocation and isolation of the heart. The tho-
rax was opened by an incision and the heart was removed
immediately. The pericardium and other adjacent tissues
were removed quickly and aorta was cut at the point of
bifurcation, so that about 1 cm of aorta remained intact.
The isolated heart was immediately placed in a petri dish
containing the Krebs–Henseleit buffer at 37C and aerated
with 5%CO2 in O2 (carbogen). The composition of Krebs–
Henseleit buffer was (in mM): 118 NaCl, 4.7 KCl, 1.2
MgSO47H2O, 1.25 CaCl2, 24 NaHCO3, 1.1 KH2P04 and
10 glucose with pH 7.4.
After gentle squeezing, the heart was attached to the
cannula of Langendorrf’s apparatus through aorta. The
aerated and thermostatically maintained perfusion fluid is
allowed to flow into the heart through aorta. A thread is
attached through a clip to the apex of the heart and passed
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over a freely moving pulley; another end of the thread was
attached to the lever of the isotonic BioScience transducer,
which was connected through the amplifier to the
oscillograph.
Protocol
Following cannulation, the retrograde perfusion through
the aorta was allowed. Once the heart was mounted on the
experimental station, perfusion pressure was adjusted to
achieve the satisfactory spontaneous heart beat. Usually
10–15 min was sufficient to attain the steady state. Ini-
tially, the normal rhythmic and synchronous cardiac
activity and the coronary flow (CF) were observed and
recorded, which served as control. All the parameters were
observed for another 20 min before employing the test
sample.
Not more than one full dose–response curve was
determined on one preparation. Any heart which shown
abnormal pattern of the activity was discarded. In some
experiments L-NAME (0.01 mM) and indomethacin
(0.01 mM) were added to the buffer to avoid the influence
of prostaglandin I2 (PGI2) and nitric oxide (NO) on the
effect of test substances. All these antagonists were used to
avoid complications in data interpretation [21].
Dose cycle
After a control period, different doses of the crude extract
of Acorus calamus and its fractions (mg/mL) and standard
drugs were injected gently into the rubber tubing attached
to the cannula at the interval of 5–10 min. Measurements
were performed both in the controls and in the test. The
maximal effect is taken into account during 10 min time
following the administration of each dose of test sample(s).
Rate of the ventricular contractions, as heart rate (HR) was
measured from number of beats per min. Force of ven-
tricular contractions (FVC) was calculated in centimeter
from the baseline. CF was calculated from the total number
of drops per min, as described previously [19, 20].
Bovine coronary artery
The protocol of Campbell et al. [22] was followed with
some modifications. Bovine hearts were purchased from a
local slaughterhouse, and sections of the left anterior
descending coronary artery were dissected and cleaned of
connective tissue. The artery was cut into 2-mm-diameter
rings. Arterial rings were equilibrated in normal Krebs
buffer consisting of (in mM) 119 NaCl, 4.8 KCl, 2.4
NaHCO3, 3.8 CaCl2, 1.2 KH2PO4, 1.2 MgSO4, 11 glucose
and 0.02 EDTA at 37C, aerated with carbogen and
equilibrated for 1.5 h. KCl (40 mM) was added to the
chamber until reproducible maximal contractions were
maintained. U46619 (20 nM) was used to induce sustained
contraction.
Experimental protocol
The integrity of endothelium was confirmed by relaxation
to bradykinin (1 lM). In some vessels, the endothelium
was deliberately removed by gently rubbing the lumen with
forceps and the success of procedure was confirmed by the
inability of bradykinin to induce vasodilatation [22]. The
rings were suspended on a pair of stainless steel hooks in a
5 mL organ chamber. One hook was anchored to a steel
rod, and the other was attached to a force transducer (Fort-
100, WPI, UK). Vessels were equilibrated for 1.5 h under
2 g of resting tension. KCl (40 mM) was added until
reproducible contractions were obtained. The thromboxane
mimetic, U46619 (20 nM) was then administered to induce
sustained contraction. Cumulative additions of the test
materials along with standards, such as methacholine and
arachidonic acid, were made. To establish the mechanisms
of relaxation, some vessels were treated with TEA (1 lM),
SKF525A (10 lM), glibenclamide (1 lM), indomethacin
(1 lM) or vehicle, and the concentration–response curve
was determined. Similar experiments were performed with
[K?] in the Krebs solution reduced to 0 mM or increased to
4.8–20 mM. Equivalent changes in [Na?] were made to
maintain isotonicity. Results were expressed as percent
relaxation, with 100% relaxation representing the basal
pre-U46619 tension. Changes in isometric tension were
recorded and analyzed through a force transducer (Fort-
100, WPI, UK), coupled with bridge amplifier (Transbridge
TBM4) and PowerLab (ML845) data acquisition system
(ADInstruments, Sydney, Australia).
Effect on high K? induced contractions in bovine
coronary arterial preparations
To assess the inhibitory effect of Acorus calamus extract
on Ca2? movement through voltage dependent Ca2?
channels, K?, as KCl, was used which produced sustained
contractions by depolarization of the preparations [23]. The
Acorus calamus extract and its fractions were used in a
cumulative fashion, to obtain concentration-dependent
inhibitory responses. The relaxation of K? (40 mM) pre-
contraction was expressed as percent of the control
response. Changes in isometric tension were recorded and
analyzed through a force transducer (Fort-100, WPI, UK),
coupled with bridge amplifier (Transbridge TBM4) and
PowerLab (ML845) data acquisition system (ADInstru-
ments, Sydney, Australia).
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Statistics
All the data expressed are mean ± standard error of the
mean (SEM), and the median effective concentrations
(EC50 values) are given with 95% confidence intervals
(CI). The statistical parameter applied is the student t test
with P \ 0.05 noted as significantly different (GraphPad
program, GraphPad, San Diego, CA, USA), concentration




In isolated perfused rabbit heart the effect of Ac.Cr and its
fractions were observed on three different parameters, such
as, force of ventricular contraction (FVC), HR and CF. When
tested, Ac.Cr partially (55–60%) suppressed HR, FVC and
CF, with respective EC50 values of 0.13 (0.07–0.24), 0.11
(0.06–0.19) and 1.10 mg/mL (0.52–1.80), as shown in
Fig. 1a. The suppressant effect of Ac.Cr on CF was weak as
compared to its effect on HR and FVC.
The Ac.nHexane completely suppressed FVC, partially
suppressed HR, with respective EC50 values of 0.17
(0.13–0.22) and 0.82 mg/mL (0.43–1.55) while caused
modest increase in CF (Fig. 1b). Ac.EtAc completely
suppressed FVC and partially inhibited both HR and CF,
with respective EC50 values of 0.17 (0.13–0.23), 0.70
(0.49–1.0) and 0.54 mg/mL (0.33–0.87) as shown in
Fig. 1c.
Methacholine partially inhibited FVC, completely sup-
pressed HR while caused a modest increase in CF (Fig. 2a).
Arachidonic acid exhibited weak inhibitory effect on FVC,
no effect on HR, while caused a dominant increase in CF,
which was about 80% of the control (Fig. 2b). Verapamil
caused complete suppression of FVC, HR and CF (Fig. 2c).
Effect on bovine coronary artery
The bovine coronary vessels that were pre-contracted with
U46619 (20 nM) produced endothelium-dependent relax-
ation to Ac.Cr, with EC50 value of 2.5 mg/mL (1.8–3.11).
The relaxation was inhibited in vascular ring preparations
without functional endothelium (denuded) and in the
presence of increasing concentrations (4.8 and 20 mM) of
K? in the buffer (Fig. 3a); similar effects were observed
with methacholine (Fig. 4a) and arachidonic acid (Fig. 4c).
Pretreatment of the arterial rings with TEA (1 lM) and
SKF525A (10 lM), did not alter basal tension or contrac-
tions to U46619, however, inhibited the relaxations to
Fig. 1 Effect of a the crude extract of Acorus calamus (Ac.Cr) and
its fractions; b nHexane (Ac.nHexane) and c ethylacetate (Ac.EtAc)
on the heart rate (HR), force of ventricular contraction (FVC) and
coronary flow (CF) in isolated rabbit heart preparations in
Langendorrf’s experiment. *P [ 0.05 versus base line. Values shown
are mean ± SEM (n = 3–4)
Fig. 2 Effect of a methacholine, b arachidonic acid and c verapamil
on the heart rate (HR), force of ventricular contraction (FVC) and
coronary flow (CF) in isolated rabbit heart preparations in Langendorrf’s
experiment. *P [ 0.05 versus base line; ***P [ 0.0001 versus base line.
Value shown are the mean ± SEM (n = 4)
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Ac.Cr (Fig. 3b), similar to methacholine (Fig. 4b) and
arachidonic acid (Fig. 4d). The relaxant effect of Ac.Cr
remained unchanged in arterial rings pretreated with gli-
benclamide (1 lM), L-NAME (1 lM) and indomethacin
(1 lM).
Ac.nHexane also caused relaxation of U46619-induced
vasoconstrictions in a concentration-related manner, with
EC50 value of 0.21 mg/mL (0.17–0.29). The relaxation to
Ac.nHexane was inhibited in the presence of increasing
concentrations (4.8 and 20 mM) of K? in the buffer
(Fig. 3c) and rings pretreated with TEA (1 lM) and
SKF525A (10 lM) (Fig. 3d) and remained unchanged in
rings pretreated with glibenclamide (1 lM), L-NAME
(1 lM) and indomethacin (1 lM).
Ac.EtAc also produced relaxation to U46619-
induced vasoconstrictions in a concentration-related
manner but the effect remained unchanged in presence
of increasing concentrations of K? (4.8 and 20 mM) in
the buffer (Fig. 3e) and in rings pretreated with
TEA(1 lM), SKF525A(10 lM) and indomethacin
(1 lM) (Fig. 3f).
Effect on high K? precontractions in bovine
coronary artery
In isolated bovine coronary arterial rings, cumulative
addition of crude extract of Acorus calamus caused inhi-
bition of the high K? (20 mM) precontractions with EC50
value of 0.34 mg/mL (0.28–0.49) (Fig. 5). Among the
tested fractions, the ethylacetate fraction was more potent
than the parent crude extract and nHexane fraction, with














































































Fig. 3 Isolated bovine left descending coronary arterial rings with
intact and denuded endothelium were constricted with U46619
(20 nM) and cumulative effect of the crude extract of Acorus calamus
(Ac.Cr) and its fractions was determined. a, c, and e depict,
respectively, the effect of Ac.Cr and its nHexane (Ac.nHexane) and
ethylacetate (Ac.EtAc) fractions in presence of varying concentra-
tions (4.8 and 20 mM) of K?, in the Kreb’s solution. b, d, and f show,
respectively, the effect of Ac.Cr, Ac.nHexane and Ac.EtAc in the
intact arterial rings in the absence and presence of TEA (1 lM),
SKF525A (10 lM), glibenclamide (1 lM) and L-NAME (1 lM) and
in the denuded rings preparations. *P [ 0.05 versus base line;
**P [ 0.001 versus base line. Value shown are mean ± SEM
(n = 5–10)
Fig. 4 Isolated bovine left descending coronary arteries were con-
stricted with U46619 (20 nM) and cumulative effect of methacholine
and arachidonic acid was determined in intact and denuded endothe-
lium rings. a and c depict the effect of methacholine and arachidonic,
respectively, in the arterial rings in presence of varying concentrations
(4.8 and 20 mM) of K? in the Krebs’ solution. b and d show,
respectively, the effect of methacholine and arachidonic acid in
denuded and in intact arterial rings preparations in the absence and
presence of TEA (1 lM) and SKF525A (10 lM). ***P [ 0.0001
versus base line. Values shown are mean ± SEM (n = 8–14)
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Discussion
As an extension of a previous study [14], the crude extract
and fractions of Acorus calamus were further studied based
on its medicinal use in ischemic heart diseases [3].
Langendorrf’s perfused rabbit heart and isolated bovine
coronary arterial preparations were used. The aim here was
to study the functional nature of the pharmacological effect
of Ac.Cr and its fractions on CF, as mediated through
EDHF, in addition to their effect on FVC and HR. The
effect of other mediators of endothelial origin, such as, NO
and PGI2 were ruled out by the addition of L-NAME, a NO
synthase inhibitor [24] and indomethacin, a PGI2 inhibitor
[25] to the Krebs–Henseleit solution. Under these experi-
mental conditions, Ac.Cr caused partial (C60%) inhibition
of FVC, HR and, CF. Verapamil, a standard calcium
channel blocker [26], caused complete suppression.
Ac.EtAc completely suppressed FVC and partially inhib-
ited HR and CF. The nHexane fraction unlike the crude
extract suppressed FVC, partially inhibited HR while
caused modest increase in CF, similar to methacholine and
or arachidonic acid. The complete or partial suppression of
the cardiac parameters by the crude extract and its fractions
may involve inhibitory effect on calcium channels.
When tested in isolated bovine coronary arterial ring
preparations pre-contracted with high K? (20 mM), the
ethylacetate fraction was found to be more potent than the
parent crude extract and the nHexane fraction thus
suggesting that the possible presence of Ca2? channel
blocking component observed in terms of inhibitory effect
against high K? [27], as reported in the previous study [14]
is concentrated in the ethylacetate fraction. Calcium
channel blockers, such as verapamil are known to possess
negative inotropic and chronotropic effects [28, 29] and
depress CF in isolated heart preparations, where CF is
largely dependent on myocardial contractility [30], so the
direct effect of such drugs on CF is not evident [31]. The
partial inhibitory effect of the crude extract on cardiac
parameters might be of potential clinical advantage, as
complete inhibitory effect, like that of verapamil, can lead
to myocardial suppression, as a side effect.
The functional nature of the effect on CF was further
studied in isolated bovine coronary arterial preparation.
The endothelium has emerged as an important regulator of
vascular tone. Several soluble mediators released by the
endothelium are involved in these vascular effects, such as
prostacyclin, NO and EDHF. The EDHF release hyperpo-
larizes the underlying smooth muscle cells by activation of
K? channels, the most frequent being KCa channels [32].
The activity of EDHF may be distinguished from NO;
EDHF activity is blocked by TEA, inhibitors of KCa [21],
or by high K? but not by L-NAME or glibenclamide,
inhibitor of KATP channel [33].
When tested on the U46619, thromboxane prostanoid
receptors activator [34], precontractions in bovine coronary
arterial preparations with intact endothelium, Ac.Cr
exhibited downstream effect, which was inhibited in
presence of increasing concentrations of K? in the buffer,
similar to methacholine and arachidonic acid. Potassium
causes vasodilatation at low concentrations (\14 mM)
through hyperpolarization and activation of Na?–K?
ATPase [34]. At higher ([14 mM) concentrations K?
cause depolarization and contraction of the smooth muscle
because potassium at high concentration inactivates all K?
channels [35] and allows voltage-gated calcium channels to
open [27]. Thus K? functions as an EDHF within the
concentration window of 4.8–14 mM [34, 36]. The inhi-
bition of the relaxant effect of Ac.Cr in the presence of
increasing concentration of K?, suggests that Ac.Cr
mediates the downstream effect through activation of KCa
and may act as EDHF. This hypothesis was further con-
firmed when the induced relaxation of crude extract was
blocked in presence of TEA and remained unchanged in
the presence of glibenclamide and L-NAME, excluding the
involvement of KATP channels or NO.
Methacholine, a known EDHF releasing agent [37], is
also known to stimulate the release of several arachidonic
acid metabolites which further causes relaxation and
hyperpolarization, the effect is sensitive to inhibitors of
cytochrome P450, such as, SKF525A [21]. Interestingly, the
downstream effect of Ac.Cr was also attenuated when
Fig. 5 Effect of the crude extract of Acorus calamus (Ac.Cr) and its
ethylacetate (Ac.EtAc) and nHexane (Ac.nHexane) fractions on high
K? (20 mM)-induced contractions in isolated bovine left descending
coronary arterial preparations. Values shown are mean ± SEM
(n = 10–16)
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repeated in the presence of SKF525A. This indicates that
Ac.Cr caused the EDHF-mediated downstream effect
possibly via the release of arachidonic acid metabolites,
similar to methacholine. Arachidonic acid, in coronary
endothelial cells, is known to metabolize by cytochrome
P450 activity to epoxyeicosatrienoic acids (EETs) [38].
Studies from a number of laboratories indicate that EETs
function as an EDHF [39]. The EDHF mediated hyperpo-
larization and subsequent vascular relaxation is uninflu-
enced in the presence of L-NAME, NO synthase inhibitor
or indomethacin, a cyclooxygenase inhibitor. However, the
relaxation induced by arachidonic acid is blocked by
inhibitors of cytochrome P450 [38], as well as TEA and
high K?. When tested in another set of experiment, the
downstream effect of Ac.Cr remained unchanged in
the presence of L-NAME and indomethacin, suggesting
the release of EDHF from the endothelial cells, similar to
that observed with methacholine and arachidonic acid.
Ac.nHexane caused an endothelium-dependent down-
stream effect against U46619-induced contractions in cor-
onary arteries, which was attenuated in the presence of
high K?, TEA and SKF525A, similar to that observed with
methacholine and arachidonic acid. The Ac.nHexane was
about ten times more potent in inhibiting U46619-induced
contractions than the parent crude extract, which indicate
that the EDHF-mediated relaxant activity is concentrated in
this particular fraction.
Interestingly, the ethylacetate fraction caused inhibition
of the U46619-induced contractions but the effect
remained unchanged in the presence of high K?, TEA,
SKF525A or indomethacin. This suggests that this effect
may be due to the presence of calcium channel blocking
(CCB) constituent in the extract of Acorus calamus,
because the ethylacetate fraction was more potent in
inhibiting high K? precontraction in isolated bovine cor-
onary arterial rings than the crude extract and nHexane
fraction.
Endothelium-dependent relaxation and hyperpolariza-
tion mechanism is impaired in ischemic heart diseases [40]
and different K? channels have been identified in myo-
cardial cells [41] where their activation may function as a
downstream mechanism in ischemic preconditioning and
reduction in myocardial ischemic injury [32]. Endothe-
lium-dependent hyperpolarization and subsequent vascular
relaxation are inhibited by blockers of KCa channels in
coronary arteries [42], suggesting that the activation of KCa
channels plays an important role in coronary vasodilatation
[43]. Thus, the vascular relaxant effect of the crude extract
and its nHexane fraction in coronary artery, which is sup-
posed to be mediated via the release of EDHF, strongly
support and provides pharmacological rationale to the
medicinal use of Acorus calamus in ischemic heart dis-
eases, though further chemical isolation and molecular
characterization, would provide more insight into the
effect.
In conclusion, these data indicate that the crude extract
of Acorus calamus possesses coronary vasodilator effect,
mediated possibly through EDHF. The partial cardiac
depressant effect may be of added value as complete sup-
pression may lead to cardiac arrest. This study provides
pharmacological rationale, with respect to the medicinal
use of Acorus calamus in ischemic heart diseases.
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